These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 29090451)

  • 41. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
    Sawkar AR; D'Haeze W; Kelly JW
    Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Newborn screening for lysosomal storage disorders.
    Nakamura K; Hattori K; Endo F
    Am J Med Genet C Semin Med Genet; 2011 Feb; 157C(1):63-71. PubMed ID: 21312327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Replacement Therapies in Metabolic Disease.
    Keller AS; Keller Iv TCS; DeLalio LJ; Shahab G; Yang Y; Murphy SA; Shu X; Isakson BE
    Curr Pharm Biotechnol; 2018; 19(5):382-399. PubMed ID: 29921204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic approaches to lysosomal storage diseases.
    Kaye EM
    Curr Opin Pediatr; 1995 Dec; 7(6):650-4. PubMed ID: 8776014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging therapies for neuropathic lysosomal storage disorders.
    Kelly JM; Bradbury A; Martin DR; Byrne ME
    Prog Neurobiol; 2017 May; 152():166-180. PubMed ID: 27725193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS.
    Giugliani R; Vairo F; Kubaski F; Poswar F; Riegel M; Baldo G; Saute JA
    Lancet Child Adolesc Health; 2018 Jan; 2(1):56-68. PubMed ID: 30169196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.
    Beck M
    Hum Genet; 2007 Mar; 121(1):1-22. PubMed ID: 17089160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene therapy of lysosomal storage disorders.
    Salvetti A; Heard JM; Danos O
    Br Med Bull; 1995 Jan; 51(1):106-22. PubMed ID: 7767637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Update on treatment of lysosomal storage diseases.
    Bruni S; Loschi L; Incerti C; Gabrielli O; Coppa GV
    Acta Myol; 2007 Jul; 26(1):87-92. PubMed ID: 17915580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
    Parenti G
    EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The status of hematopoietic stem cell transplantation in lysosomal storage disease.
    Malatack JJ; Consolini DM; Bayever E
    Pediatr Neurol; 2003 Nov; 29(5):391-403. PubMed ID: 14684234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging drugs for the treatment of mucopolysaccharidoses.
    Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G
    Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatable lysosomal storage diseases in the advent of disease-specific therapy.
    Peters H; Ellaway C; Nicholls K; Reardon K; Szer J
    Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Newborn screening of lysosomal storage disorders.
    Marsden D; Levy H
    Clin Chem; 2010 Jul; 56(7):1071-9. PubMed ID: 20489136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic approaches for neuronopathic lysosomal storage disorders.
    Schiffmann R
    J Inherit Metab Dis; 2010 Aug; 33(4):373-9. PubMed ID: 20162366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
    Parenti G; Andria G; Valenzano KJ
    Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging drugs for lysosomal storage diseases.
    Beck M
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):495-507. PubMed ID: 20557271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene therapy for lysosomal storage disorders.
    Barranger JM; Novelli EA
    Expert Opin Biol Ther; 2001 Sep; 1(5):857-67. PubMed ID: 11728220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapies for neurological disease in the mucopolysaccharidoses.
    Anson DS; McIntyre C; Byers S
    Curr Gene Ther; 2011 Apr; 11(2):132-43. PubMed ID: 21291356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.